The Management of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation: A Survey among Interventional Cardiologists from Eight European Countries.

Details

Serval ID
serval:BIB_37A49EFADEDA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The Management of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation: A Survey among Interventional Cardiologists from Eight European Countries.
Journal
Journal of Interventional Cardiology
Author(s)
Rubboli A., Dewilde W., Huber K., Eeckhout E., Herzfeld I., Valencia J., Windecker S., Airaksinen K.E., Lip G.Y.
ISSN
1540-8183 (Electronic)
ISSN-L
0896-4327
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
25
Number
2
Pages
163-169
Language
english
Notes
Publication types: JOURNAL ARTICLE
Abstract
Purpose:  To evaluate the current management, and adherence to recommendations, of patients on oral anticoagulation (OAC) undergoing coronary stent implantation (PCI-S). Methods:  By means of a contact person who had been previously identified in 8 European countries, a questionnaire was electronically forwarded between April and July 2010 to the national institutions where PCI-S is performed. Results:  A total of  202 questionnaires (median response rate: 50%, range 33-78%) was received. The prevalence of OAC patients among those undergoing PCI-S is mostly reported 5-10% (97%). The peri-procedural pharmacological management mostly encompasses: preprocedural OAC interruption and bridging with low-molecular-weight heparin (59%), intraprocedural administration of an unfractionated heparin bolus (81%), and use of glycoprotein IIb/IIIa inhibitors on an individual basis (79%). The radial approach is reported as the preferred option (58%), as well as the implantation of bare metal stents (76%). Triple therapy (warfarin, aspirin, clopidogrel) is the most frequently prescribed (80%), generally for 1 month after bare metal stent (77%) and for at least 12 months after drug-eluting stent (60%). Throughout triple therapy, the International Normalized Ratio is mostly targeted to the lower end of the therapeutic range (77%), and gastric protection is routinely prescribed (69%), mostly by giving proton-pump inhibitors (70%). Conclusions:  Among the 202 interventional cardiologists from the 8 European countries interviewed, the management of patients on OAC undergoing PCI-S appears variable and only partially adherent to currently available recommendations. (J Interven Cardiol 2012;25:163-169).
Pubmed
Web of science
Create date
05/05/2012 15:41
Last modification date
20/08/2019 13:26
Usage data